Patent ID: 8980823
Filing Date: 2015-03-17
Classification: A61K,C12N

Abstract:
1. A method for treating a subject having a vascular disorder, said method comprising administering a therapeutic effective amount of a nanoparticle to the subject to treat the disorder, wherein the vascular disorder is selected from the group consisting of sickle cell disease, an angiogenesis-mediated disorder, pulmonary hypertension, and combinations thereof, and wherein the nanoparticle comprises a poly L-arginine polymer and a Factor VIIa inhibitor conjugated to or encapsulated in the poly L-arginine polymer, wherein the Factor VIIa inhibitor is selected from the group consisting of: Factor VIIa inhibitor I in which R 1 is independently selected from the group consisting of hydrogen and a NO donor at positions 3, 4, 5, and 6; Factor VIIa inhibitor II in which R 1 is independently selected from the group consisting of hydrogen and a NO donor at positions 3, 4, and 6 and in which R 2 is independently selected from the group consisting of hydrogen and a NO donor at positions 2, 4, 5, and 6, wherein for each position at which R Factor VIIa inhibitor III in which R 1 is independently selected from the group consisting of hydrogen and a NO donor at positions 3, 4, 5, and 6; and Factor VIIa inhibitor IV in which R 1 is independently selected from the group consisting of hydrogen and a NO donor at positions 3, 4, and 5; wherein the Factor VIIa inhibitor includes at least one NO donor, and wherein for each position in each Factor VIIa inhibitor of Factor VIIa inhibitors I, II, III, and IV at which R